share_log

Ladenburg Thalmann Initiates Coverage On Sonnet BioTherapeutics With Buy Rating, Announces Price Target of $7

Benzinga ·  Nov 27, 2023 09:00

Ladenburg Thalmann analyst Ahu Demir initiates coverage on Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy rating and announces Price Target of $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment